SOURCE: BioTech Medics, Inc.

November 14, 2006 09:40 ET

BioTech Medics Announces Pinksheets Quotation

DALLAS, TX -- (MARKET WIRE) -- November 14, 2006 -- BioTech Medics, Inc. (PINKSHEETS: BTMD) announced today that BioTech Medics has met Pinksheets standards to supply adequate current information about the Company for Pinksheets to commence quotation of BTMD shares.

BioTech Medics is completing its Form 15c2-11 with an expectation toward filing with the NASD. The Company's CPA firm has been engaged to review of the Company's financial statements in order to issue a statement that BTMD complies with GAAP.

Chairman / CEO, Keith A. Houser commented, "This is another significant milestone in the growth of the Company. The Pinksheets daily quotation will help bring visibility and continued awareness to what we believe is a vast market. Additionally, I want to personally thank our loyal shareholders who continue to have faith in our Board and Management team and support the long-term success of BioTech Medics."

BioTech Medics owns and operates a Pain Management & Wellness Center in Dallas. Affiliated centers are also located in Albuquerque, NM; Los Angeles, CA; and Overland Park, Kansas. The Company intends to have Pain Management & Wellness Centers in the top 100 cities of the US over the next three years. A new international center is scheduled to open in Panama in January, 2007.

BioTech Medics offers quick and safe, drug-free pain relief via the NeuroLase Therapeutic Medical laser, one of the most powerful FDA-cleared Class III B lasers in the USA approved for use on the entire body. The NeuroLase is for the temporary relief of muscular, skeletal and arthritic pain.

BioTech Medics also owns proprietary US Letters of Patent and manufactures SHBAN Antibacterial Solution. Recent clinical tests in England proved SHBAN kills the avian bird flu virus, and 99% of most viruses; yet it is non-toxic to humans, animals and the environment when used as directed.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed.

Contact Information

  • Contact:
    Investor Relations
    Phone: 800-200-2458